Genedrive plc develops and commercializes rapid pharmacogenetic testing solutions aimed at improving patient outcomes through personalized medicine. The company offers a near-patient testing platform that identifies genetic variants affecting drug response, enabling healthcare professionals to make informed treatment decisions quickly. Its primary products include the Genedrive® MT-RNR1 ID Kit, which helps prevent antibiotic-induced hearing loss in neonates, and the Genedrive® CYP2C19 ID Kit, designed for optimizing antiplatelet therapy in stroke patients. Genedrive operates primarily in the UK and collaborates with the National Health Service (NHS) to enhance clinical care pathways.